Abstract: Additives for paper making are disclosed herein. Specifically, the additives are wax-free alternatives to conventional coatings, including ASA, AKD and optionally an acrylic containing composition. Other additives may be included in the coating, such as cationic particles or compositions. The coatings may be used at a variety of points during the paper making process, including on the calender stack and in the wet end.

Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

Abstract: An internal size and a method for sizing board, such as liquid packaging board, with a hydrophobising internal size containing oxetanon derivative or 2-oxetanon. The main part of the hydrocarbon chains R? and R? of the oxetanon derivative or 2-oxetanon are derived from linear fatty acids, and ?20 w-%, typically 2 to 15 w-%, most typically 5 to 12 w-% of the hydrocarbon chains are derived from branched and mainly saturated fatty acids.

Abstract: An internal size and a method for sizing board, such as liquid packaging board, with a hydrophobising internal size containing oxetanon derivative or 2-oxetanon. The main part of the hydrocarbon chains R′ and R″ of the oxetanon derivative or 2-oxetanon are derived from linear fatty acids, and ≦20 w-%, typically 2 to 15 w-%, most typically 5 to 12 w-% of the hydrocarbon chains are derived from branched and mainly saturated fatty acids.

Abstract: Alpha-methylenelactone is produced from butyrolactone and valerolactone by the addition of formaldehyde in a supercritical fluid.

Abstract: Alpha-methylenelactones are produced from butyrolactone and valerolactone by the addition of formaldehyde in a supercritical fluid in the presence of a catalyst and a phase transfer agent.

Abstract: This invention pertains to a process for making &agr;-methylenelactones and &agr;-substituted hydrocarbylidene lactones. More specifically, the present invention obtains high yields of &agr;-methylene-&ggr;-butyrolactone by heating &ggr;-butyrolactone and diethyl oxalate in the presence of a base. The second step comprises treatment of the &agr;-oxalyl enolate salt with formaldehyde to afford the &agr;-methylene-&ggr;-butyrolactone.

Abstract: The present invention is directed towards a process for the preparation of enantiomerically enriched 4-hydroxymethyl-&ggr;-butyrolactone (I).

Abstract: The present invention relates to photochromic 2H-naphtho[1,2-b]pyrans as well as their use in synthetic resins of all types, especially for ophthalmic purposes. In particular, the present invention relates to photochromic naphthopyran compounds, for which a further ring system is bonded to the f side of the naphthopyran. The inventive photochromic dyes generally have the general formula (I) wherein n, R1, R2, R3, X, B and B′ are defined as in claim 1. The inventive compounds are distinguished by good darkening and decolorizing properties and a very good service life.

Abstract: A carrier containing silicon carbide, inorganic bonding component, and at least one oxide selected from the group consisting of a niobium oxide, an antimony oxide, and a tungsten oxide carries at least one oxide selected from the group consisting of a vanadium oxide and a molybdenum oxide as catalytically active component. An inexpensive catalyst for catalytic oxidation use can be thus offered that does not change its properties over a period of time, that boasts stable catalytic activity over a period of time, and that is suitable for, e.g., manufacture of an acid anhydride and a nitrile compound by conducting a catalytic gas-phase oxidation reaction (partial oxidation reaction) on a hydrocarbon.

Abstract: A method is provided for enhancing transmembrane transport of exogenous molecules. The method comprises contacting a membrane of a living cell with a complex formed between said molecules and ligands selected from biotin, biotin analogs and other biotin receptor-binding ligands, and/or folic acid, folate analogs and other folate receptor-binding ligands to initiate receptor mediated transmembrane transport of the ligand complex. The method is used for the efficient delivery of peptides, proteins, nucleic acids and other compounds capable of modifying cell function into plant, animal, yeast, and bacterial cells.

Abstract: The compounds of the following structural formula (I) ##STR1## ar 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase inhibitors and useful as antihypercholesterolemic agents for the treatment of disease in which the inhibition of cholesterol biosynthesis would be useful, such as arteriosclerosis, hyperlipidemia and familial hypercholesterolemia.